Despite the rapid evolution of oncology treatments globally — from interventional therapies to radiopharmaceutical innovations — adoption across Latin America remains inconsistent and, in many cases, significantly delayed. While regulatory pathways are often perceived as the primary barrier, the reality is far more complex. Structural inefficiencies, fragmented healthcare ecosystems, and operational limitations play a decisive role in determining whether a technology truly reaches patients. Understanding these underlying dynamics is essential for any company aiming to enter or expand within the region.

ALS | COSTA
Strategic Perspectives on Oncology Innovation and Market Development